Active Ingredient History
Paroxetine, also known by the trade names Paxil and Seroxat. PAXIL (paroxetine hydrochloride) is an orally administered psychotropic drug. It is the hydrochloride salt of a phenylpiperidine compound identified chemically as (-)-trans-4R-(4'fluorophenyl)-3S-[(3',4'-methylenedioxyphenoxy) methyl] piperidine hydrochloride hemihydrate. It is used to treat major depressive disorder, obsessive-compulsive disorder, social anxiety disorder, panic disorder, posttraumatic stress disorder, generalized anxiety disorder and premenstrual dysphoric disorder. Paroxetine is a potent and highly selective inhibitor of neuronal serotonin reuptake. Paroxetine likely inhibits the reuptake of serotonin at the neuronal membrane, enhances serotonergic neurotransmission by reducing turnover of the neurotransmitter, therefore it prolongs its activity at synaptic receptor sites and potentiates 5-HT in the CNS; paroxetine is more potent than both sertraline and fluoxetine in its ability to inhibit 5-HT reuptake. Compared to the tricyclic antidepressants, SSRIs have dramatically decreased binding to histamine, acetylcholine, and norepinephrine receptors. The mechanism of action for the treatment of vasomotor symptoms is unknown. Paroxetine, a phenylpiperidine derivative, was originally developed in 1975 by Jorgen Buus-Lassen and associates working in a small Danish company Ferrosan. Paroxetine was the second SSRI synthesized by Buus-Lassen In 1975. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Anxiety Disorders (approved 1992)
Obsessive-Compulsive Disorder (approved 1992)
Stress Disorders, Post-Traumatic (approved 1992)
Agoraphobia (Phase 4)
Alcoholism (Phase 4)
Anovulation (Phase 1)
Anxiety (Phase 4)
Anxiety Disorders (Phase 4)
Arthritis, Rheumatoid (Phase 1/Phase 2)
Bipolar Disorder (Phase 4)
Burning Mouth Syndrome (Phase 3)
Combat Disorders (Phase 4)
Coronary Artery Disease (Phase 4)
Cytochrome P-450 CYP2D6 (Phase 1)
Cytochrome P-450 CYP3A (Phase 1)
Dementia (Phase 4)
Depression (Phase 4)
Depressive Disorder, Major (Phase 4)
Diabetic Neuropathies (Phase 1)
Drug Interactions (Phase 1)
Dysthymic Disorder (Phase 4)
Endothelial Cells (Phase 4)
Fibromyalgia (Phase 4)
Healthy Volunteers (Phase 4)
Heart Disease Risk Factors (Phase 4)
Heart Diseases (Phase 2)
Hepatitis C, Chronic (Phase 3)
HIV Infections (Phase 1/Phase 2)
Hot Flashes (Phase 3)
Hypercapnia (Phase 1)
Hypertension (Phase 4)
Idiopathic Pulmonary Fibrosis (Phase 1)
Irritable Bowel Syndrome (Phase 4)
Menopause (Phase 4)
Mental Disorders (Phase 4)
Metabolic Detoxication, Phase I (Phase 1)
Multiple Sclerosis (Phase 3)
Myocardial Infarction (Phase 2)
Neuralgia (Phase 3)
Obsessive Behavior (Phase 4)
Obsessive-Compulsive Disorder (Phase 4)
Pain (Phase 4)
Parkinson Disease (Phase 3)
Phobia, Social (Phase 4)
Phobic Disorders (Phase 4)
Postmenopause (Phase 4)
Premature Ejaculation (Phase 3)
Premenstrual Dysphoric Disorder (Phase 4)
Premenstrual Syndrome (Phase 4)
Prostatic Hyperplasia (Phase 1)
Prostatic Neoplasms (Phase 2/Phase 3)
Psychophysiologic Disorders (Phase 3)
Respiratory Insufficiency (Phase 1)
Schizophrenia (Phase 3)
Sepsis (Phase 2)
Shock, Septic (Phase 2)
Sleep Apnea, Obstructive (Phase 4)
Stress Disorders, Post-Traumatic (Phase 4)
Suicidal Ideation (Phase 4)
Tinnitus (Phase 4)
Vasomotor System (Phase 3)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
